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Abstract background Multidrug-resistant tuberculosis (MDR-TB) is posing a great threat to global TB
control. The burden in Zambia is not well defined because routine surveillance data are scarce. We
reviewed national MDR-TB data for the last decade to inform future public health policy with
respect to MDR-TB in Zambia.
method Retrospective review of national surveillance of MDR-TB data, TB programme and
laboratory reports between 2000 and 2011.
results The total number of DSTs performed during this 11-year period was 2 038 and accounted
for 2.6% (2 038/78 639) of all the retreatment cases notified. The total number of diagnosed MDR-
TB cases for this period was 446, of which 56.3% (251/446) were male and 41.7% (186/446)
female. Only one child was found to have MDR-TB. Poly-drug resistance accounted for 18.9% (172/
911) of the DR-TB cases and 8.4% of the total DSTs. 8.8% (80/911) of the DR-TB cases showed
either rifampicin mono- or poly-resistance other than MDR-TB. No XDR-TB was reported. There
were no data available on DR-TB and HIV co-infection. Only 65 MDR-TB patients were notified
and put on second-line treatment according to WHO guidelines.
conclusions Multidrug-resistant tuberculosis may be an emerging challenge in Zambia. There is a
need to invest in improving the capacity of the TB programme to detect and manage MDR-TB.
keywords tuberculosis, multidrug-resistant tuberculosis, surveillance, retreatments, diagnosis,
Zambia
Introduction
Tuberculosis (TB) has remained a huge challenge to glo-
bal health almost 20 years after WHO declared it a glo-
bal emergency (Zumla et al. 2012) .The availability of
cost-effective anti-TB drugs facilitated the recommenda-
tion and implementation of the directly observed treat-
ment short-course (DOTS) strategy, as a TB control
strategy especially for low- and middle-income countries
(Raviglione & Pio 2002). Although notable progress has
been made globally towards TB control with incident
rates showing a downward trend over the past few years,
the emergence of resistant strains, especially multidrug-
resistant tuberculosis (MDR-TB), defined as TB resistant
to both isoniazid and rifampicin, poses a great challenge
to achieving targets which will translate into actual
impact in terms of TB control and eventual elimination
(WHO 2010; Zumla et al. 2012). The global burden of
MDR-TB in 2010 was estimated to be 650 000 cases, of
which the majority was reported from Eastern Europe
and Asia, with sub-Saharan Africa accounting for a very
small and undefined proportion (WHO 2010; Zignol
et al. 2012a). In 2008, MDR-TB killed more than
150 000 people globally (WHO 2012a).
Global surveillance has mainly been based on reports
from surveys conducted previously while routine surveil-
lance data are limited (Zignol et al. 2012a; Zumla et al.
2012). The emergence of extensively drug-resistant TB
(XDR-TB) is causing even greater concern for future TB
control strategies (Gandhi et al. 2010), especially in
highly HIV-prevalent countries, where the prognosis of
these patients varies significantly from very poor with
© 2013 John Wiley & Sons Ltd 1
Tropical Medicine and International Health doi:10.1111/tmi.12183
volume 00 no 00
100% mortality (Cooke et al. 2011) to relatively better
outcomes in other cases (Orenstein et al. 2009).
In sub-Saharan Africa, MDR-TB surveillance data have
been scarce in the past years and few countries have con-
ducted drug resistance surveys (Wright et al. 2009; WHO
2010; Zignol et al. 2012a).The limitation is mainly due
to inadequate diagnostic capacity and drug susceptibility
testing (DST) in most sub-Sahara African countries
(Wright et al. 2009). Zambia has made good progress in
tuberculosis (TB) control with the estimated prevalence
rates showing a downward trend and having very good
treatment outcomes in new cases and retreatment cases
regardless of the HIV status of the patients (Kapata et al.
2012; WHO 2012b).
In Zambia, TB is mainly diagnosed by microscopy,
using Ziehl–Neelsen (ZN) stains (Kapata et al. 2011);
culture and DST have been performed in Zambia since
the late 1990s, although there are currently no reliable
records and reports on this before the year 2000. Ini-
tially, routine culture and DST were only performed at
the National Reference Laboratory (NRL), which catered
for the whole country. The capacity to perform culture
and DST gradually increased from one referral centre
(NRL) to three by the year 2008, which included the Uni-
versity Teaching Hospital (UTH) and the Tropical Dis-
eases Research Centre (TDRC). These laboratories cater
for a population of approximately 13.4 million across a
land surface area of about 752 000 square kilometres.
We conducted a retrospective review to understand the
MDR-TB situation in Zambia, to ascertain the magnitude
of the problem and to discuss possible mitigation issues to
improve MDR-TB control efforts and patient management.
Methods
Review period and documents
We retrospectively reviewed reports from 2000 to 2011.
Records reviewed included laboratory registers from the
University Teaching Hospital, Tropical Disease Research
Centre and the Chest Diseases Laboratory (National TB
Reference Laboratory), National TB programme review
reports, annual TB returns and notifications, Ministry of
Health assessment reports and TB laboratory reports
including external quality assurance reports. Cases
reported from operational research studies were not
included in the review.
Treatment regimens
The treatment regimens for Zambia were designed fol-
lowing WHO guidelines as follows: (i) Category I for all
new TB cases, (ii) Category II for all retreatment TB
cases and (iii) Category IV for all MDR-TB patients. The
Category I treatment regimen was changed in 2007, from
the 8-month regimen of rifampicin, isoniazid, pyrazina-
mide and ethambutol (RHEZ) in fixed dose combination
in the intensive phase for 2 months followed by
6 months of isoniazid and ethambutol (EH) in fixed dose
combination in the continuation phase, to the 6-month
regimen of RHEZ for 2 months initial phase followed by
4 months of RH in the continuation phase.
Diagnosis
The mainstay of diagnosis in Zambia is smear micros-
copy; culture and DST is recommended to be performed
only on samples from all patients enrolled on treatment
as retreatment cases; those who fail to respond to treat-
ment and all those who had interrupted treatment. The
drugs routinely tested for are rifampicin, isoniazid,
ethambutol and streptomycin. TB diagnosis is free in
the public sector.
Definitions
The definition for a retreatment case was a case of TB
diagnosed in a patient who had been treated before with
first-line TB drugs for more than 1 month. Mono-resis-
tant TB is defined as drug resistance to any one first-line
TB drug. MDR-TB was defined as TB resistant to both
isoniazid and rifampicin, while poly-resistant TB was
defined as drug resistance to two or more first-line TB
drugs excluding MDR-TB. XDR-TB was defined as
MDR-TB that is resistant to at least one injectable sec-
ond-line TB drug (kanamycin, amikacin, capreomycin)
and any of the fluoroquinolones.
Multidrug-resistant tuberculosis diagnosis strategy
The diagnosis of drug-resistant TB (DR-TB) and MDR-
TB is made by collecting sputum samples from the sus-
pected patients and subjecting the specimen to culture on
either solid media using L€owenstein–Jensen (LJ) or on
liquid media using Mycobacteria Growth Indicator Tube
(MGIT) and then performing DST on the positive sam-
ples. The suspected MDR-TB patients are usually the
patients who fail first-line treatment and have sputum
smear-positive results at three to 5 months of treatment
and at the end of treatment; all retreatment cases are also
considered to be MDR-TB suspects. The results of the
DST are thereafter sent back to the referring facility
where the patients are then given the results and notified
into the treatment register and started on second-line
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treatment. External quality assurance for the three labo-
ratories is conducted by the supranational laboratories
annually through proficiency testing. The notification
reports and patients record cards are kept at the treat-
ment facilities and regular monitoring, and supervision is
conducted at these facilities by TB programme staff on a
quarterly basis to ensure good quality data are collected.
These reports are mainly based on the public sector,
which provides for more than 90% of TB diagnosis and
treatment facilities (Kapata et al. 2011).
Results
Retreatment cases
The total number of all types of retreatment cases for the
11-year period was 78 639 accounting for 12.9%
(78 639/609 724) of the total number of all forms of TB
cases notified (Table 1). Smear-positive retreatment cases
and other retreatment cases accounted for 4.4% (26 970/
609 724) and 8% (51 669/609 724) of all cases,
respectively.
The total number of DSTs performed during the
11-year period was 2 038 which accounted for 2.6%
(2 038/78 639) of all the retreatment cases notified. Only
0.3% of patients notified with any form of TB were sub-
jected to the DST. The number of DSTs performed
increased from 69 in 2000 to 207 in 2011, whereas the
notification rate for the same period declined from 504/
100 000 population in 2000 to 356/100 000 in 2011.
Children accounted for 6% (4 718/78 639) of the total
number of retreatment cases notified. The number of
male retreatment cases notified for the same period was
47 970, accounting for 61% of the total retreatment
cases.
Drug-resistant (DR) TB cases
The total number of MDR-TB cases diagnosed in the
11 years under review was 446; this accounted for 49%
(446/911) of the total cases that were diagnosed as
DR-TB from all the reference laboratories, and 22%
(446/2 038) of the total DSTs (Table 2). Of the 911
DR-TB cases, 12.6% (115) were mono-resistant to isoni-
azid, 4.8% (44) to rifampicin, 4.1% (37) to ethambutol
and 10.7% (97) to streptomycin. Poly-resistance
accounted for 18.8% (172/911) of the DR-TB cases and
8.4% of the total DSTs, of which poly-resistance includ-
ing rifampicin resistance, excluding MDR-TB, accounted
for 8.8% (80/911) of DR-TB cases. The average age of
patients with DR-TB was 39.4 years CI (38.1, 40.6);
44% (CI 40.9, 47.8) were females and 56% (CI 52.1,
59.1) were males. No XDR-TB cases were reported, and
Table 1 Number and percentage of retreatment cases from the notifications of all forms of TB (2000–2011)
Year
Notification all forms
(rate per 100 000 population)
Number of smear-positive
retreatments (%)
Number of other
retreatments (%)
Number of all
retreatments (%) Number of DSTs
2000 49 806 (504) 1 455 (2.9) – 1 455 (2.9) 69
2001 52 757 (523) 1 522 (2.9) 6 498 (12.3) 8 020 (15.2) 63
2002 45 836 (440) 2 193 (4.8) 92 (0.2) 2 285 (5.0) 90
2003 55 275 (514) 2 538 (4.6) 3 412 (6.2) 5 950 (10.8) 96
2004 58 070 (524) 2 485 (4.3) 6 021 (10.4) 8 506 (14.6) 176
2005 53 569 (468) 2 039 (3.8) 5 524 (10.3) 7 563 (14.1) 439
2006 51 179 (434) 2 464 (4.8) 5 614 (11.0) 8 078 (15.8) 345
2007 50 415 (415) 2 442 (4.8) 5 833 (11.6) 8 275 (16.4) 79
2008 47 333 (378) 2 278 (4.8) 5 236 (11.1) 7 514 (15.9) 175
2009 48 510 (376) 2 485 (5.1) 5 444 (11.2) 7 929 (16.3) 171
2010 48 408 (365) 2 595 (5.3) 6 310 (13.0) 8 905 (18.4) 128
2011 48 566 (356) 2 474 (5.1) 1 685 (3.5) 4 159 (8.6) 207
Total no. 609 724 26 970 51 669 78 639 2 038
Table 2 Number and percentage of different resistance patterns
out of the total drug-resistant TB cases
Type of resistance Number
Percentage
(%) CI
Isoniazid mono-resistance 115 12.6 10.46–14.78
Rifampicin
mono-resistance
44 4.8 3.43–6.22
Ethambutol
mono-resistance
37 4.1 2.78–5.34
Streptomycin
mono-resistance
97 10.7 8.64–12.65
Poly-resistance 172 18.8 16.83–20.84
MDR-TB 446 49 45.70–52.20
TOTAL DR-TB 911 100
Resistance to pyrazinamide not routinely determined in all three
reference laboratories.
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only three cases of DR-TB were children younger than
15 years. No data were available on DR-TB and HIV co-
infection for the review period.
Notification of MDR-TB cases
Data on initiation of second-line treatment were only
available from 2010. For the 2-year period from 2010–
2011, there were a total of 175 MDR-TB cases, of which
just 65 (37%) were initiated on second-line treatment.
There was a fourfold increase in the number of cases
notified by year from 18 in 2000 to 85 in 2011 as shown
in Figure 1.
Discussion
In Zambia, a national drug resistance survey was con-
ducted in 2001, reporting the prevalence of MDR-TB to
be low at 1.8% and 2.3% in new and retreatment cases,
respectively (Mulenga et al. 2010). The number of cases
diagnosed in the past 11 years with drug susceptibility
testing performed on just 3% of the expected cases raises
concerns with regard to selection bias and an overall
underestimate as the sample cannot be considered repre-
sentative. Nearly half of all the DR-TB cases diagnosed
during the review period were MDR-TB. The number of
MDR-TB cases detected through the routine surveillance
system appears to have been increasing. This increase
could be attributed to the improvement and expansion of
the reference laboratory network and capacity to perform
DSTs, including the introduction of newer methods of
diagnosis such the Mycobacterium Growth Indicator
Tube (MGIT). The MGIT services improved the turn-
around time of performing culture and DST thus led to
more tests being performed (Muyoyeta et al. 2009). Our
study has highlighted that DST among the eligible sam-
ples is inadequate. National TB control guidelines state
that all retreatment cases should be subjected to culture
and DST upon notification, but adherence to this guide-
line is low. The restriction of DST services to a limited
number of centralised laboratories is clearly a major
obstacle to improving DST coverage. It needs to be inves-
tigated whether it would be more cost-effective to install
DST services in more laboratories, or to invest in logistics
for the transporting sputum samples to the existing refer-
ence laboratories for culture and DST, from high-risk
patient groups and other cases where DR-TB is sus-
pected.
The numbers of retreatment patients in the first 3 years
(Table 1) of the review show some inconsistencies, mainly
because during this period, the NTP was just being re-or-
ganised after disruption in the late 1990s (Mwaba et al.
2003). However, the small number the retreatment cases
in 2011 needs to be explored. The majority of the MDR-
TB cases (39%) were diagnosed in the latter 2 years. Con-
sidering that the cure rates for retreatment cases range
from 50 to 70% (Kapata et al. 2011; WHO 2012b), it is
likely that the cases that were selected to be sent for DST
were at very high risk of being MDR-TB, such as treatment
failures in the previously treated cohorts. Further reviews
are required to understand this; especially that the preva-
lence of MDR-TB is low based on the drug resistance sur-
vey of 2001 (WHO 2010). However, other studies have
shown rates of 9.5% MDR-TB in high-risk places, such as
prisons (Habeenzu et al. 2007) and in tertiary referral hos-
pitals such as the UTH, where the prevalence of MDR-TB
in hospitalised patients was 16.2% (O’Grady et al. 2012).
These findings underscore the need for improved routine
surveillance and screening of patients, through culture and
DST or indeed through the use of better and quicker diag-
nostics such as the Xpert MTB/RIF assay; proactive screen-
ing of cases such as routine screening on admission of
patients into medical wards of the hospital should be advo-
cated for to ensure that cases are not missed especially in
high-risk groups such as patients who failed Category 1
treatment (Bates et al. 2012; O’Grady et al. 2012).
There was only one case of MDR-TB cases in children
under the age of 15 years; this may not be representative
of the true situation as only three childhood cases had
DST performed. In a study conducted at the UTH, 2
childhood cases of MDR-TB were diagnosed when active
case finding was applied using the Xpert MTB/RIF on
gastric lavage aspirates in a study conducted within a
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Figure 1 Number of MDR-TB cases diagnosed by year from
2000 to 2011.
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1-year period (Bates et al. 2013). This underscores the
importance of MDR-TB surveillance in children through
the routine programme and active case finding in risk
groups such as contacts of known or suspected infectious
MDR-TB patients, especially using the Xpert MT/RIF
assay, as there is also evidence in the subregion of a
childhood MDR-TB emerging problem (Zignol et al.
2012b).
Due to inadequate reporting and recording, no data
were available on MDR-TB / HIV co-infections. Co-
treatment of MDR-TB and HIV is extremely debilitat-
ing, with both medical and social impediments to
adherence (Isaakidis et al. 2013). More investments
should be made in improving data capturing to include
data on HIV co-infection in MDR-TB (Klinkenberg
et al. 2012).
The presence of other types of resistance patterns
(Table 2), including rifampicin mono-resistance, indi-
cates that DR-TB must be fully addressed and managed
in terms of more investment into better diagnostics and
availability of drugs as this may eventually complicate
further TB control programmes if left unchecked. DR-
TB other than MDR-TB accounted for 465 cases during
the period under study when DST was only performed
in 3% of the suspected cases. Almost all the DSTs were
actually performed on pulmonary cases from which spu-
tum samples could be collected and not from cases with
extrapulmonary TB. MDR-TB that presents as EPTB
was not documented and yet MDR-TB in EPTB does
occur, although diagnosis is usually problematic (Mau-
rya et al. 2012). Considering the high number of EPTB
in retreatment patients, ways to improve diagnosis in
this group of patients should be explored. There were
no data on extensively drug-resistant TB as no routine
DST to second-line drugs is currently performed in
Zambia.
Conclusion
Multidrug-resistant tuberculosis in Zambia may increas-
ingly pose a challenge and reverse the achievements
made so far if not well managed. At global level, only
16% of patients requiring second-line treatment actually
receive it (WHO 2012a), and so our proportion of 37%
for 2010–2011 is encouraging, but more investments are
needed to improve reporting systems, and for the devel-
opment of better diagnostics and drugs to detect and
treat MDR-TB. The NTP should be strengthened to
improve the management of MDR-TB in Zambia while
also realising that the best method to control MDR-TB
is to ensure a good TB treatment programme for drug
susceptible TB.
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